GNRHR
Gonadotropin-releasing hormone receptor
As of the edition of 20 October 2026, GNRHR (gonadotropin-releasing hormone receptor, UniProt P30968) has 21 drugs tested at it and 38 companies on the list, 3 on route A and 12 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P30968
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 1
- Disease areas
- Urinary and reproductive; Cancer; Pregnancy and women's health; Skin and connective tissue; Hormones; Mental health; Nutrition and metabolism; Inherited and neonatal
- Registered trials of its drugs
- 898
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 15 |
| Active | 1 |
| Went quiet | 4 |
| Stopped | 1 |
| Total | 21 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Leuprolide | Marketed | Phase 4 | Ended 2026 |
| Goserelin | Marketed | Phase 4 | none listed |
| Degarelix | Marketed | Phase 4 | none listed |
| Triptorelin | Marketed | Phase 4 | none listed |
| Relugolix | Marketed | Phase 4 | Ends 2033 |
| Cetrorelix | Marketed | Phase 4 | none listed |
| Ganirelix | Marketed | Phase 4 | none listed |
| Gonadorelin | Marketed | Phase 4 | none listed |
| Elagolix | Marketed | Phase 4 | Ends 2039 |
| Linzagolix | Marketed | Phase 3 | none listed |
| Buserelin | Marketed | Phase 4 | none listed |
| Triptorelin acetate | Marketed | Phase 4 | none listed |
12 of 21 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 12 |
| Engaged | 15 |
| Undetermined | 8 |
| Total on the list | 38 |
The other 35 companies at GNRHR
In the product38 companies in all; 35 are not named here, and no score is.
See the 38 companies at GNRHR, ranked, with the facts behind eachRequest access. Nothing is shown until you do.